Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Sara W. Quist*, Alexander V. van Schoonhoven, Stephan J.L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M.T. van Loon, Jeroen H.J. Paulissen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

19 Downloads (Pure)

Abstract

Background: In the Netherlands, more than one million patients have type 2 diabetes (T2D), and approximately 36% of these patients have chronic kidney disease (CKD). Yearly medical costs related to T2D and CKD account for approximately €1.3 billion and €805 million, respectively. The FIDELIO-DKD trial showed that the addition of finerenone to the standard of care (SoC) lowers the risk of CKD progression and cardiovascular (CV) events in patients with CKD stages 2–4 associated with T2D. This study investigates the cost-effectiveness of adding finerenone to the SoC of patients with advanced CKD and T2D compared to SoC monotherapy. Methods: The validated FINE-CKD model is a Markov cohort model which simulates the disease pathway of patients over a lifetime time horizon. The model was adapted to reflect the Dutch societal perspective. The model estimated the incremental costs, utilities, and incremental cost-effectiveness ratio (ICER). Sensitivity and scenario analyses were performed to assess the effect of parameter uncertainty on model robustness. Results: When used in conjunction with SoC, finerenone extended time free of CV events and renal replacement therapy by respectively 0.30 and 0.31 life years compared to SoC alone, resulting in an extension of 0.20 quality-adjusted life years (QALYs). The reduction in renal and CV events led to a €6136 decrease in total lifetime costs per patient compared to SoC alone, establishing finerenone as a dominant treatment option. Finerenone in addition to SoC had a 83% probability of being dominant and a 93% probability of being cost-effective at a willingness-to-pay threshold of €20,000. Conclusion: By reducing the risk of CKD progression and CV events, finerenone saves costs to society while gaining QALYs in patients with T2D and advanced CKD in the Netherlands.

Original languageEnglish
Article number328
Number of pages16
JournalCardiovascular Diabetology
Volume22
Issue number1
DOIs
Publication statusPublished - Dec-2023

Keywords

  • Chronic kidney disease
  • Cost-effectiveness-analysis
  • Costs
  • Finerenone
  • QALYs
  • Type 2 diabetes

Cite this